Agios Pharmaceuticals EBITDA 2012-2024 | AGIO

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Agios Pharmaceuticals ebitda from 2012 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Agios Pharmaceuticals ebitda from 2012 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Related Stocks
Company Name	Market Cap
Abbott Laboratories (ABT)	$200B
Stryker (SYK)	$141B
Boston Scientific (BSX)	$128B
Medtronic (MDT)	$113B
EssilorLuxottica (ESLOY)	$112.7B
Lonza Group Ag (LZAGY)	$45.3B
Haleon (HLN)	$43.5B
GE HealthCare Technologies (GEHC)	$40.4B
ResMed (RMD)	$36.5B
Terumo (TRUMY)	$30.3B
Koninklijke Philips (PHG)	$25.9B
Zimmer Biomet Holdings (ZBH)	$21.6B
Baxter (BAX)	$18.4B
Insulet (PODD)	$17.2B
Smith & Nephew SNATS (SNN)	$10.8B
Bio-Rad Laboratories (BIO)	$10.4B
BellRing Brands (BRBR)	$8.9B
Demant (WILYY)	$8.4B
Lantheus Holdings (LNTH)	$6.1B
Haemonetics (HAE)	$4.4B
ICU Medical (ICUI)	$4.4B
TG Therapeutics (TGTX)	$4.3B
Prestige Consumer Healthcare (PBH)	$4B
Envista Holdings (NVST)	$3.7B
Perrigo (PRGO)	$3.7B
Neogen (NEOG)	$3.4B
Shandong Weigao Medical Polymer (SHWGF)	$3B
GN Store Nord (GNNDY)	$2.9B
QuidelOrtho (QDEL)	$2.6B
LeMaitre Vascular (LMAT)	$2.3B